Assessing the immunogenicity of an inactivated monovalent vaccine in the endangered African wild dog (Lycaon pictus)
Nicole Anderson, Ian Smith
Vaccine: X · 2019
doi:10.1016/j.jvacx.2019.100006 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Captive held African wild dogs (Lycaon pictus) were vaccinated with a commercially available inactivated canine parvovirus (CPV) vaccine licensed for use in domestic dogs. Serological responses were recorded by testing for viral antibodies with the haemagglutination inhibition test (HAI) following a vaccination schedule involving two initial inoculations a month apart and an annual booster. Vaccines were delivered by hand injection or remotely (i.e. by dart). All naïve dogs vaccinated with Parvac® did seroconvert as determined by canine antibody titres ≥ 1:80 in one or more samples collected after inoculation. Duration of immunity (DOI) within the first year persisted for approximately 98 days only. To enable greater immunological protection revaccination should occur more frequently than once in a calendar year. No significant differences in the seroprotection rate were observed when comparing route of administration. Keywords: Lycaon pictus, Canine parvovirus, Vaccination, Duration of immunity, Canid, Endangered species
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.